Merck Beats Third-Quarter Forecasts on Keytruda and Gardasil
Merck's third-quarter results exceeded forecasts, supported by strong performance from Keytruda and Gardasil.
Related stories
Lilly Raises Sales Outlook by $5.5 Billion, Cuts EPS Forecast
Eli Lilly reported third-quarter non-GAAP EPS of $7.48 versus analysts’ consensus of $5.68 and revenue of $24.4 billion versus $22.58 billion. Revenue rose 39%, with volume up 53%
M impact | EARNINGS | Oct 29, 2026, 03:41 PM UTC
Eurobank Reports 14% Rise in Adjusted Nine-Month 2026 Net Profit
Adjusted net profit for the nine months of 2026 rose 14% year over year.
M impact | EARNINGS | Oct 29, 2026, 03:36 PM UTC
Eurobank Reports Nine-Month Net Profit of €1.16 Billion
Eurobank said net profit for the nine months was €1.16 billion, compared with €1.03 billion in the same period of 2025.
M impact | EARNINGS | Oct 29, 2026, 03:34 PM UTC
Hershey warns cost-of-living pressures may cool Halloween demand
Hershey's third-quarter net sales slightly exceeded LSEG expectations.
M impact | EARNINGS | Oct 29, 2026, 03:31 PM UTC
ServiceNow Shares Fall Nearly 15% After Earnings Shortfall
ServiceNow shares plunged nearly 15% Thursday morning after an earnings shortfall, despite revenue of $4.106 billion, up 20.5% year over year and slightly above a…
M impact | EARNINGS | Oct 29, 2026, 03:27 PM UTC
Basler shares jump after third annual forecast increase this year
Basler shares rose after the company raised its annual forecast for the third time this year.
M impact | EARNINGS | Oct 29, 2026, 03:23 PM UTC